Ovarian cancer recurrence:“is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

作     者：Tanja Pejovic Katherine Fitch Gordon Mills 

作者机构：Knight Cancer InstituteOregon Health&Science UniversityPortlandOR 97239USA. Department of Obstetrics&GynecologyOregon Health&Science UniversityPortlandOR 97239USA. 

出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)

年 卷 期：2022年第5卷第2期

页      面：451-458页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Oregon Health and Science University  OHSU 

主　　题：PARP inhibitors olaparib niraparib ovarian cancer maintenance therapy 

摘      要：PolyADP ribose polymerase inhibitors(PARPi)have transformed the treatment of ovarian *** in high-grade serous ovarian cancer(HGSOC),a disease characterized by homologous recombination deficiency(HRD),PARPi have had a rapid and profound impact on the disease course,as well as biologic and biomarker definitions of HGSOC,thereby creating a paradigm shift in the approach to *** this review,we discuss the role of PARPi in the maintenance treatment of HGSOC,its effect on platinum sensitivity,and cross-resistance between platinum and PARP inhibitors.